Genome-Wide Sequencing for Unexplained Developmental Disabilities and Multiple Congenital Anomalies

Draft Recommendation

Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, recommends publicly funding whole exome sequencing as a second-tier test (that is, when chromosomal microarray testing results in no diagnosis) for people with unexplained developmental disabilities and multiple congenital anomalies

Thank you for your comments.

The public feedback period for this topic has ended. All comments will be considered before a final recommendation is made and posted here. Use the tabs below to learn more about this topic and download supporting draft documents, including the full assessment report. To be notified once a final recommendation is posted here, sign up for our newsletter.

About This Topic
Supporting Documents

People with unexplained developmental disabilities or conditions from birth (known as congenital anomalies) might have many tests done over a period of years trying to find a diagnosis for their condition. A genetic diagnosis can help people and their families better understand their condition and help them connect with others who have the same condition.

Genome-wide sequencing, as whole-exome or whole-genome sequencing, can examine the entire genetic makeup of a person in a single test, capturing genetic information that other genetic tests can miss.

This health technology assessment looked at how effective and cost-effective both whole-exome and whole-genome sequencing are for people with unexplained developmental disabilities and other unexplained conditions from birth. It also looked at the budget impact of publicly funding these tests and at the experiences, preferences, and values of people, families, and clinicians supporting people with these conditions.

The assessment was conducted in collaboration with the Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH completed two reports: a rapid review of the qualitative evidence of patient preferences and a technology review of the ethical considerations.

Read the full Health Technology Assessment report for more information.

Genome-Wide Sequencing for Unexplained Developmental Disabilities and Multiple Congenital Anomalies: A Health Technology Assessment (PDF)
September 2019

Related Resources

Genome-Wide Sequencing for Unexplained Developmental Delays and Multiple Congenital Anomalies: A Rapid Qualitative Review (PDF)
May 2019

Genome-Wide Sequencing: Ethical Considerations (PDF)
September 2019

Use of this site, and the interpretation of the information contained here, is subject to important terms and conditions. Use of this site and information except in accordance with these terms and conditions is expressly prohibited.

About Health Quality Ontario

Health Quality Ontario is the provincial lead on the quality of health care. We help nurses, doctors and other health care professionals working hard on the frontlines be more effective in what they do—by providing objective advice and data, and by supporting them and government in improving health care for the people of Ontario.

We focus on making health care more effective, efficient and affordable through a legislative mandate of:

Reporting to the public, organizations, government and health care providers on how the health system is performing,
Finding the best evidence of what works, and
Translating this evidence into clinical standards; recommendations to health care professionals and funders; and tools that health care providers can easily put into practice to make improvements.

For more information about Health Quality Ontario, visit hqontario.ca.